Analysis of degradomic profiles for different stages of breast cancer, breast benign tumors and different molecular subgroups of breast cancers, and other types of cancers (e.g., uterine, liver, lung cancers, etc) and diseases (e.g., inflammation) are needed for statistical validation of which aberrances of the degradomic profile and/or which substrate sequence domains generating the peptidome peptides are specific to or unique for BCP before the BCP degradomic profile and/or individual peptidomic peptides reported in this work can be directly applied for the diagnostic purpose. This evidence concerns the gene OPN1SW and breast benign neoplasm.